Business Context and Reporting Period
Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 8-K (Current Report)
Date of Report: March 5, 2026
Reporting Period: The filing addresses events occurring between February 19, 2026, and March 5, 2026, specifically regarding stock listing compliance.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding corporate governance and listing status. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Regulatory Status Change: The Company regained compliance with the Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement).
Stock Price Performance: The common stock maintained a minimum closing bid price of $1.00 per share for 10 consecutive business days (February 19, 2026, through March 4, 2026).
Resolution of Deficiency: This action resolves a deficiency previously notified by Nasdaq in June 2025 and extended in December 2025.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on March 6, 2026, confirming the regained compliance. The matter regarding the Minimum Bid Price Requirement is now closed.
Risks and Contingencies: The filing addresses the risk of delisting due to failure to meet the $1.00 minimum bid price. As of the report date, this specific risk has been mitigated. No other risks, contingencies, or unusual items are disclosed in this document.
Investor Verification Checklist
- Verify the current trading price of INTS on the Nasdaq Stock Market to ensure continued compliance with the $1.00 minimum bid price.
- Review the attached Press Release (Exhibit 99.1) for any additional operational updates not detailed in the 8-K text.
- Confirm the Company's status as an "Emerging Growth Company" and any associated reporting exemptions.
- Check subsequent filings for any new Nasdaq correspondence or financial updates, as this 8-K contains no financial data.